Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 11, 2010

Evotec to Screen for Hits against Active Biotech Immune Disorder and Cancer Target

  • Evotec signed a high-throughput screening agreement with Active Biotech. The company is tasked with identifing and validating novel hits against an Active Biotech target involved in immune disorders and cancer.

    Screening will focus on Evotec’s own small molecule Lead Discovery Library. The firm will leverage its high-throughput screening and surface plasmon resonance screening capabilities.

    “We are impressed by the excellent quality of Evotec’s Lead Discovery Library, which we believe will enable us to generate high-quality hits, ensuring a smooth transition to medicinal chemistry activities,” comments Dorthe da Graça Trhige, Active Biotech’s director of development. “Importantly, the hits identified in the HTS will complement the ongoing lead optimization of compounds identified in house.”

     



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »